Bonus Material-27_Khurana_COPD_2025

Pdf Summary

This comprehensive pulmonary board review on Chronic Obstructive Pulmonary Disease (COPD), presented by Dr. Sandhya Khurana, covers the disease’s pathophysiology, diagnosis, management, and complications.<br /><br />COPD is a heterogeneous chronic lung disease characterized by persistent respiratory symptoms and progressive airflow obstruction due to airway and alveolar abnormalities. It has a high global prevalence (~10.6%) with 3 million annual deaths and is expected to rise, particularly affecting women and low-middle income countries. Key risk factors include tobacco smoke, indoor biomass smoke, occupational exposures, and genetic factors such as alpha-1 antitrypsin (AAT) deficiency.<br /><br />Diagnosis relies on spirometry confirming airflow limitation (post-bronchodilator FEV1/FVC < 0.7). The GOLD system classifies severity based on FEV1 and symptom assessments (mMRC, CAT), combined into ABCDE groups to guide treatment. The BODE index (BMI, airflow obstruction, dyspnea, exercise capacity) predicts mortality better than FEV1 alone.<br /><br />Pharmacologic treatment includes bronchodilators (SABA, SAMA, LABA, LAMA), with LAMA/LABA combinations superior to monotherapy in improving lung function, symptoms, and exacerbation prevention. Inhaled corticosteroids (ICS) combined with LABA reduce exacerbations and mortality in high-risk patients but elevate pneumonia risk. Triple therapy (ICS/LABA/LAMA) shows the greatest benefit for exacerbation reduction and mortality.<br /><br />Nonpharmacologic management emphasizes smoking cessation, pulmonary rehabilitation, and long-term oxygen therapy for hypoxemia, which improves survival. Selected patients with severe emphysema and low exercise capacity may benefit from lung volume reduction surgery or bronchoscopic interventions. AAT deficiency should be suspected in early-onset COPD, non-smokers, and those with basal panacinar emphysema, with augmentation therapy indicated in severe cases.<br /><br />COPD exacerbations are mainly triggered by infections and worsen lung function and survival. Frequent exacerbations predict faster decline and higher mortality. Management includes bronchodilators, systemic corticosteroids, antibiotics when bacterial infection is suspected, and noninvasive ventilation for respiratory failure.<br /><br />Common comorbidities such as cardiovascular disease, osteoporosis, GERD, and obstructive sleep apnea contribute to COPD morbidity and mortality. COPD also increases risk of poor COVID-19 outcomes.<br /><br />In summary, COPD requires multifaceted management tailored by severity and exacerbation risk. Interventions including smoking cessation, optimized inhaled therapy, rehabilitation, oxygen, and procedural options enhance quality of life and survival. Recognizing disease heterogeneity and comorbidities is vital for optimal care.

Meta Tag

Concept Chronic Obstructive Pulmonary Disease

Concept Smoking

Concept COPD Exacerbation

Concept GOLD Stage

Concept Spirometry

Concept Bronchodilator

Concept Smoking Cessation

Keywords

COPD

Chronic Obstructive Pulmonary Disease

spirometry

GOLD classification

FEV1/FVC

bronchodilators

LAMA/LABA

inhaled corticosteroids

pulmonary rehabilitation

alpha-1 antitrypsin deficiency

Chronic Obstructive Pulmonary Disease

Smoking

COPD Exacerbation

GOLD Stage

Spirometry

Bronchodilator

Smoking Cessation

COPD